Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma

Bortezomib is a proteasome inhibitor, approved for treating newly diagnosed and relapsed multiple myeloma (MM). This realworld, multicenter, observational, non-interventional study of bortezomib was designed to collect and analyze prospective data in Taiwanese patients with relapsed or refractory MM...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shang-Yi, Chen, Tsai-Yun, Kuo, Ching-Yuan, Chen, Yeu-Chin, Lin, Sheng-Fung, Chang, Ming-Chih, Lv, Xinzhu, Yang, Betty, Chang, Cheng-Shyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379781/
https://www.ncbi.nlm.nih.gov/pubmed/30858932
http://dx.doi.org/10.4081/oncol.2019.377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379781/
https://www.ncbi.nlm.nih.gov/pubmed/30858932
http://dx.doi.org/10.4081/oncol.2019.377

Ejemplares similares